Camp Lejeune cancer lawsuit

Will Camp Lejeune Justice Act Courts Recognize CDC Study's Expanded Cancer List

An expanded list of types of cancer caused at Camp Lejeune could double the number of administrative claims

Monday, February 19, 2024 - The pivotal question hovering over nearly 2000 Camp Lejeune water lawsuits is whether the judges presiding over these cases will acknowledge the findings of the latest CDC study, which widens the scope of cancers attributed to water contamination. The study, as reported by the Associated Press (AP), has expanded the list to include certain types of leukemia, and lymphoma, as well as cancers affecting the lung, breast, throat, esophagus, and thyroid. Thousands of individuals, including US Marines, civilian employees, their families, and the survivors of those who succumbed to these illnesses, are being urged to seek advice from a Camp Lejeune water attorney and pursue legal action through water cancer lawsuits to pursue significant lump-sum financial compensation. As per the guidelines outlined in the Camp Lejeune Justice Act, individuals must initially file administrative claims with the Navy AG before proceeding with a lawsuit. If these administrative claims are summarily dismissed or left unaddressed for six months, the option to file a lawsuit becomes available. The expansion of the list of cancers presumed to be linked to Camp Lejeune could potentially lead to a doubling or more of the number of claims and lawsuits arising from the rejection of administrative claims. Lung cancer, non-Hodgkin's lymphoma, breast, and leukemia are among the top ten most frequently occurring types of cancer in the US. Thousands of Marines who lost children to childhood leukemia may now be encouraged to file administrative claims and lawsuits. RollCall.com recently addressed the CDC's study's credibility. "Researchers at the CDC spent nearly 10 years combing through health records in all 50 states and U.S. territories to document cancers among nearly 155,000 former Marines, Navy personnel, and civilian workers who had been stationed at or worked at Camp Lejeune between the mid-1970s and mid-1980s, using available records of the base population. The study also examined health records of more than 163,000 personnel based at Camp Pendleton in California during that period to compare cancer incidence among a similar population that was not exposed to tainted water."

Progress is underway in addressing Camp Lejeune water contamination claims, with anticipated bellwether trials beginning in the summer of 2024 to shape future legal actions. Four judges in the Eastern District of North Carolina have expedited compensation for victims. Since the Camp Lejeune Justice Act took effect on August 4, 2022, nearly 150,000 administrative claims and 1,500 lawsuits have been filed, reflecting the scale of the issue. Victims have until August 2024 to file administrative claims, often with the assistance of Camp Lejeune water attorneys. Legal fees are capped at 20% for administrative awards and 25% for trial awards, with firms covering upfront costs. Trials are slated for 2024, focusing on cancers such as leukemia and non-Hodgkin's lymphoma. An expedited option streamlines claims processing, a relief for terminally ill claimants. Jury trials are excluded due to time constraints, and compensatory damages are limited to $100,000 to $500,000, contingent on cancer type and exposure duration.

Information provided by CampLejeuneJusticeActClaim.com, a website devoted to providing news about Camp Lejeune Justice Act Claim, including a free no-cost, no-obligation Camp Lejeune Justice Act Claim.

More Recent Camp Lejeune Water Lawsuit News:

View all Camp Lejeune Justice Act Claim News

No-Cost, No-Obligation Claim Review for Persons or Families of Persons Who Developed Cancer After Spending 30 Days or More at Camp Lejeune between 1953 and 1988

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.


Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.